ENCINITAS, Calif., May 11, 2026
Vasa Therapeutics, a clinical-stage biotechnology company focused on therapies targeting cardiovascular and metabolic aging, announced that new research involving its investigational therapy VS-214 has been selected for oral presentation at the prestigious 2026 Vascular Discovery: From Genes to Medicine Scientific Sessions hosted by the American Heart Association (AHA). The presentation, titled “Discovery of VS-214, a long-acting apelin agonist, as a first-in-class treatment of peripheral artery disease (PAD)”, highlights the growing scientific interest surrounding the company’s innovative cardiovascular pipeline and its efforts to address major unmet needs in vascular medicine.
The oral presentation will take place during the conference’s “Peripheral Arterial Disease, Aortic Aneurysm, and Cerebrovascular Disease” session in Bellevue, Washington, and will be delivered by Artur Plonowski, MD, PhD, Chief Executive Officer of Vasa Therapeutics. Selection for an oral presentation at the AHA scientific meeting is widely recognized as an indicator of strong scientific significance and translational research potential within the cardiovascular field.
VS-214 Targets Major Unmet Need in Peripheral Artery Disease
VS-214 is a long-acting peptide analog of apelin designed to improve blood vessel growth, enhance limb perfusion, and restore muscle endurance in patients suffering from Peripheral Artery Disease (PAD). PAD is a chronic circulatory disorder caused by narrowing of the arteries, reducing blood flow to the limbs and leading to pain, impaired mobility, disability, and increased risk of amputation. The condition affects an estimated 10 to 12 million people in the United States, with prevalence continuing to rise due to aging populations and growing rates of diabetes, smoking, and hypertension.
According to Vasa Therapeutics, PAD remains one of the most underdiagnosed and undertreated cardiovascular diseases despite its substantial healthcare burden. Approximately 400 limb amputations occur daily in the United States due to PAD-related complications, highlighting the urgent need for more effective therapies capable of improving vascular function and preserving mobility. Current treatment options remain limited, with no widely available pharmacological therapy demonstrating meaningful long-term improvement in walking capacity or disease progression.
Advertisement
The company believes VS-214 could become the first pharmacological therapy designed to mimic the effects of supervised exercise therapy, currently considered one of the most effective non-invasive interventions for symptomatic PAD patients. Preclinical findings suggest that long-acting apelin agonism may stimulate neovascularization and improve circulation in ischemic limbs while enhancing muscle performance and endurance.
Apelin Biology Emerges as Promising Cardiovascular Target
Apelin signaling has increasingly attracted scientific attention as a potential therapeutic pathway in cardiovascular and metabolic disease management. The apelin pathway plays an important role in regulating vascular tone, blood flow, angiogenesis, and cardiac function, making it a promising target for next-generation cardiovascular therapeutics.
Vasa Therapeutics stated that VS-214 was specifically engineered to deliver durable apelin receptor activation while improving pharmacological stability and treatment persistence. According to CEO Artur Plonowski, the therapy represents a novel approach capable of addressing both vascular dysfunction and impaired mobility in PAD patients through disease-modifying biological mechanisms.
Industry researchers continue to identify PAD as one of the largest areas of unmet need in cardiovascular medicine, particularly as aging populations drive increasing rates of chronic vascular disease globally. Advances in targeted peptide therapeutics and vascular regenerative medicine are expected to play a growing role in future cardiovascular treatment strategies.
Cardiovascular Pipeline Expansion Supports Long-Term Growth
Vasa Therapeutics continues expanding its cardiovascular and age-related disease pipeline with four differentiated investigational assets currently targeting conditions including heart failure, peripheral artery disease, neuromuscular disorders, sarcopenia, and life-threatening arrhythmias. The company’s development strategy focuses on identifying biologically relevant mechanisms with strong translational potential capable of delivering durable clinical outcomes.
The oral presentation at the 2026 AHA Vascular Discovery meeting further strengthens the scientific visibility of the VS-214 program as the therapy advances toward a planned first-in-human clinical study expected in 2026. Analysts note that early-stage cardiovascular innovation remains a rapidly growing area within the biotechnology industry as companies pursue therapies capable of addressing chronic age-related vascular diseases through novel biological mechanisms.
The latest scientific recognition reinforces Vasa Therapeutics’ position within the emerging cardiovascular biotechnology sector while highlighting increasing momentum behind innovative therapies targeting vascular aging and peripheral artery disease.
Source: Vasa Therapeutics press release
